肾上腺髓质素对坎地沙坦治疗急性心肌梗塞大鼠的联合作用

陈广亚

0
0
浏览
下载

摘要
关键词
基金信息
论文图表
动态公开评议
相关论文
评论

The combination effect of adrenomedullin on candesartan treatment in rats with acute myocardial infarction

首发时间：2019-08-26

Chen Guangya ¹
Chen Guangya（1968-),Man,PhD Student(2005.1-2010.3),Faculty of Medicine,University of Miyazaki.Japan. Chinese company name: Xiji center for disease prevention and control.756200,Ningxia. Main research:a rat model of acute myocardial infarction. Great thanks to dear professor Kazuo Kitamura, MD, PhD

1、Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, Kiyotake, Miyazaki 889-1692, Japan

Abstract：The present study was done to see whether adrenomedullin (AM), a bioactive peptide, exerts a beneficial additive effect on treatment with candesartan, an angiotensin receptor blocker, in a rat model of acute myocardial infarction (MI). Rats with acute MI were treated with or without 10 mg/kg/day of candesartan for 10 weeks. In addition to the candesartan treatment, the MI rats were infused intraperitoneally with 1.0 μg/h AM or saline by osmotic mini-pump for 7 days immediately after MI. When compared with the placebo group, both the treatment with candesartan alone and the combination of candesartan plus AM significantly reduced heart weight, lung weight, left ventricular (LV) end-diastolic pressure, and the myocyte size and collagen fraction of non-infarct LV. There were no significant differences in these parameters between the candesartan and AM combination groups. As compared with placebo group, the ratio of the collagen volume fraction to infarct size was slightly reduced by the treatment with candesartan alone, and a significant reduction in the ratio was observed in the combination group. Thus, in MI rats treated with candesartan, AM add-on treatment in the acute phase lessened non-infarct LV fibrosis relative to the infarct size, suggesting a beneficial additive effect of AM on blockade of the action of angiotensin II.

keywords： Adrenomedullin, Bioactive peptide, Candesartan, Angiotensin II receptor blocker, Fibrosis, Heart failure.

点击查看论文中文信息

肾上腺髓质素对坎地沙坦治疗急性心肌梗塞大鼠的联合作用

陈广亚 ¹
Chen Guangya（1968-),Man,PhD Student(2005.1-2010.3),Faculty of Medicine,University of Miyazaki.Japan. Chinese company name: Xiji center for disease prevention and control.756200,Ningxia. Main research:a rat model of acute myocardial infarction. Great thanks to dear professor Kazuo Kitamura, MD, PhD

1、宫崎大学医学部，循环体液调节系，宫崎 889-1692，日本

摘要：目的：本研究旨在观察生物活性肽肾上腺髓质素(AM)对血管紧张素受体阻滞剂坎地沙坦治疗急性心肌梗塞(AMI)大鼠的叠加作用。方法：急性心肌梗塞疾病模型随机分为三组：生理盐水对照组（Control）32只，坎地沙坦治疗组（Can）20只，Can合用AM组19只。坎地沙坦用药剂量10 mg/kg/d，灌胃治疗10周。 AM用药剂量为1.0μg / h，于大鼠心肌梗塞疾病模型建立后立即于腹腔通过微型渗透泵用药7天。结果：与安慰对照组相比, 坎地沙坦治疗和联合用药组显著降低心脏重量,肺重量,左心室舒张末期压(LV-edp), 以及肌细胞大小和左心室非梗塞部分的胶原分数。坎地沙坦组与AM联合组在上述参数上无显著差异。与安慰对照组相比，单纯坎地沙坦治疗可使胶原体积分数与梗塞面积之比略有降低，而联合治疗组胶原体积分数与梗塞面积之比显著降低。结论：在坎地沙坦治疗的心肌梗塞大鼠中，AM在急性期附加治疗相对于梗塞面积减轻了左心室非梗塞部位的纤维化，表明AM对血管紧张素II的阻断作用具有有益的叠加作用。

关键词：肾上腺髓质素（AM）生物活性肽坎地沙坦（Can）血管紧张素II受体阻滞剂纤维化心力衰竭（HF）

基金：

论文图表：

引用

导出参考文献

.txt

.ris

.doc

Chen Guangya. The combination effect of adrenomedullin on candesartan treatment in rats with acute myocardial infarction[EB/OL]. Beijing:Sciencepaper Online[2019-08-26]. https://www.paper.edu.cn/releasepaper/content/201908-132.

No.****

动态公开评议

共计0人参与

动态评论进行中

全部评论

0/1000

论文编号	201908-132
论文题目	肾上腺髓质素对坎地沙坦治疗急性心肌梗塞大鼠的联合作用
文献类型
收录期刊	上传封面中文期刊英文期刊期刊名称（中文）期刊名称（英文）年，卷（）上传封面中文专著英文专著书名（中文）书名（英文）出版地出版社出版年上传封面中文译著英文译著书名（中文）书名（英文）出版地出版社出版年上传封面中文论文集英文论文集编者.论文集名称（中文） [c]. 出版地出版社出版年， - 编者.论文集名称（英文） [c]. 出版地出版社出版年，- 上传封面中文文献英文文献期刊名称（中文）期刊名称（英文）日期-- 在线地址http:// 上传封面中文文献英文文献文题（中文）文题（英文）出版地出版社,出版日期-- 上传封面中文文献英文文献文题（中文）文题（英文）出版地出版社,出版日期--
英文作者写法：中外文作者均姓前名后，姓大写，名的第一个字母大写，姓全称写出，名可只写第一个字母，其后不加实心圆点“.”, 作者之间用逗号“，”分隔，最后为实心圆点“.”, 示例1：原姓名写法：Albert Einstein,编入参考文献时写法：Einstein A. 示例2：原姓名写法：李时珍；编入参考文献时写法：LI S Z. 示例3：YELLAND R L,JONES S C,EASTON K S,et al.